Kiniksa Pharmaceuticals, Ltd.
Stock Forecast, Prediction & Price Target
Kiniksa Pharmaceuticals, Ltd. Financial Estimates
Kiniksa Pharmaceuticals, Ltd. Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. EBITDA Estimates
Kiniksa Pharmaceuticals, Ltd. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $38.54M N/A | $220.18M 471.24% | $270.25M 22.74% | Avg: $536.39M Low: $529.22M High: $543.55M avg. 98.47% | Avg: $655.24M Low: $629.20M High: $691.61M avg. 22.15% | Avg: $774.14M Low: $743.38M High: $817.11M avg. 18.14% | Avg: $837M Low: $803.74M High: $883.45M avg. 8.11% |
Net Income
% change YoY
| $-157.92M N/A | $183.36M 216.10% | $14.08M -92.31% | Avg: $42.19M Low: $-15.09M High: $82.71M avg. 199.58% | Avg: $48.42M Low: $30.92M High: $57.53M avg. 14.76% | Avg: $98.17M Low: $93.10M High: $105.25M avg. 102.74% | Avg: $62.57M Low: $59.34M High: $67.08M avg. -36.26% |
EBITDA
% change YoY
| $-156.63M N/A | $9.77M 106.23% | $-22.85M -333.85% | Avg: $102.87M Low: $101.50M High: $104.24M avg. 550.12% | Avg: $125.67M Low: $120.67M High: $132.64M avg. 22.15% | Avg: $148.47M Low: $142.57M High: $156.71M avg. 18.14% | Avg: $160.53M Low: $154.15M High: $169.44M avg. 8.11% |
EPS
% change YoY
| -$2.3 N/A | $2.64 214.78% | $0.2 -92.42% | Avg: $0.58 Low: -$0.21 High: $1.15 avg. 192.01% | Avg: $0.64 Low: $0.43 High: $0.8 avg. 9.58% | Avg: $1.37 Low: $1.29 High: $1.46 avg. 113.28% | Avg: $0.87 Low: $0.83 High: $0.93 avg. -36.26% |
Operating Expenses
% change YoY
| $186.08M N/A | $163.44M -12.16% | $238.93M 46.18% | Avg: $552.87M Low: $545.48M High: $560.25M avg. 131.39% | Avg: $675.37M Low: $648.54M High: $712.86M avg. 22.15% | Avg: $797.93M Low: $766.22M High: $842.22M avg. 18.14% | Avg: $862.71M Low: $828.43M High: $910.60M avg. 8.11% |
FAQ
What is Kiniksa Pharmaceuticals, Ltd. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 70.20% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -15.09M, average is 42.19M and high is 82.71M.
What is Kiniksa Pharmaceuticals, Ltd. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 36.72% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $529.22M, average is $536.39M and high is $543.55M.
What is Kiniksa Pharmaceuticals, Ltd. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 69.65% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.21, average is $0.58 and high is $1.15.
What is the best performing analyst?
In the last twelve months analysts have been covering Kiniksa Pharmaceuticals, Ltd. stock. The most successful analyst is Liisa Bayko.